<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01239485</url>
  </required_header>
  <id_info>
    <org_study_id>SCLSG-0901, SNUCH-RAL-0901</org_study_id>
    <nct_id>NCT01239485</nct_id>
  </id_info>
  <brief_title>Study of IRNEA (Irinotecan, Etoposide, Cytarabine) for Refractory or Relapsed Acute Leukemia in Children and Adolescents</brief_title>
  <official_title>Phase I Study of IRNEA (Irinotecan, Etoposide, Cytarabine) for Refractory or Relapsed Acute Leukemia in Children and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the maximum tolerable dose of irinotecan in
      combination with etoposide, cytarabine for refractory or relapsed acute leukemia in pediatric
      patient.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximum tolerable dose of irinotecan in combination with etoposide, cytarabine for refractory or relapsed acute leukemia in pediatric patient.</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the incidence and severity of toxicity and treatment related mortality. 2. To evaluate the response rate. 3. To determine the pharmacokinetic profile of irinotecan in combination with etoposide, cytarabine in pediatric patients.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Acute Leukemia</condition>
  <arm_group>
    <arm_group_label>Irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Chemotherapy: irinotecan, etoposide, and cytarabine daily for 5 days (on days 0, 1, 2, 3, &amp; 4) -30 min: Atropin ivs 0 hour: irinotecan X mg/m2 in D5W 100 mL IV over 60 min 0 hour: etoposide 100 mg/m2 in x3 N/S mL IV over 60 min 12 hour: cytarabine 2,000 mg/m2 over 3 hr
*if age ≤ 3 yrs: calculate all drugs in kg base (30kg=1m2) Irinotecan dose is escalated by 25-30% in successive cohorts. The starting irinotecan dose (level 1) is 20 mg/m2/dose on days 0 to 4.</description>
    <arm_group_label>Irinotecan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of ALL or AML.

          -  Prior therapy Patients must have fully recovered from the acute toxic effects of all
             prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.

               -  ALL patients must have had two or more prior therapeutic attempts defined as

                    -  Persistent (BM blast&gt;5%) initial disease after two induction attempts, or

                    -  Persistent (BM blast&gt;5%) after re-induction attempt for first relapse or

                    -  Relapse after one re-induction attempt (2nd relapse)

               -  AML patients must have one or more prior therapeutic attempts defined as

                    -  Refractory (BM blast&gt;20%) initial disease after one induction attempts, or

                    -  Persistent (BM blast&gt;5%) initial disease after two induction attempts, or

                    -  Relapse after one induction attempt (1st relapse)

               -  Relapse after stem cell transplant: Patients are eligible 12 weeks after
                  allogeneic stem cell transplant as long as patients are not actively being
                  treated for GvHD and have recovered from transplant-related toxicities. Patients
                  are eligible 8 weeks from the day of stem cell infusion for myeloablative
                  autologous stem cell transplant, if hematological and all other eligibility
                  criteria are met.

          -  Age: ≤ 21 years.

          -  Performance status: ECOG 0-2.

          -  Patients must be free of significant functional deficits in major organs, but the
             following eligibility criteria may be modified in individual cases.

               1. Heart: a shortening fraction ≥ 28%

               2. Liver: total bilirubin &lt; 2 × upper limit of normal; ALT &lt; 3 × upper limit of
                  normal.

               3. Kidney: creatinine &lt;2 × normal or a creatinine clearance (GFR) &gt; 60
                  ml/min/1.73m2.

          -  Patients must lack any active viral infections or active fungal infection.

          -  Patients (or one of parents if patients age &lt; 19) should sign informed

        Exclusion Criteria:

          1. Pregnant or nursing women.

          2. Malignant (except acute leukemia) or nonmalignant illness that is uncontrolled or
             whose control may be jeopardized by complications of study therapy.

          3. Psychiatric disorder that would preclude compliance.

          4. Patients who, in the opinion of the investigator, may not be able to comply with the
             safety monitoring requirements of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyoung Jin Kang, M.D, ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyoung Jin Kang, M.D, Ph.D</last_name>
    <phone>82 2 2072 3304</phone>
    <email>kanghj@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ji Won Lee, M.D</last_name>
    <phone>82 2 2072 0177</phone>
    <email>agnesjw@hanmail.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Chongno-gu</state>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyoung Jin Kang, M.D, Ph.D</last_name>
      <phone>82 2 2072 3304</phone>
      <email>kanghj@snu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2010</study_first_submitted>
  <study_first_submitted_qc>November 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2010</study_first_posted>
  <last_update_submitted>November 17, 2013</last_update_submitted>
  <last_update_submitted_qc>November 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2013</last_update_posted>
  <responsible_party>
    <name_title>Korea Childhood Leukemia Foundation</name_title>
    <organization>Korea Childhood Leukemia Foundation</organization>
  </responsible_party>
  <keyword>Pediatric refractory or relapsed acute leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

